Renin angiotensin system blockers, ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB) have been broadly used to treat congestive heart failure, hypertension, proteinuria and chronic kidney disease [43–45], and additionally play a significant role in improving dyslipidemia [46,47]. Here, ACE is linked to metabolic syndrome.